Eplerenone Management: Safety Thresholds, Mortality Benefit, and Monitoring
Electrolyte‑Related Discontinuation Criteria
- Hyperkalemia ≥ 6.0 mmol/L – the drug should be withheld immediately. (European Society of Cardiology guideline; Class I, Level A) 1
- Serum potassium 5.5–5.9 mmol/L – reduce the eplerenone dose by 50 %. (European Society of Cardiology guideline; Class IIa, Level A) 2
- Inability to keep potassium < 5.5 mmol/L despite dose adjustment – permanent discontinuation is recommended. (American College of Cardiology guideline; Class I, Level A) 5
Renal‑Function‑Related Management
- Serum creatinine > 310 µmol/L (≈3.5 mg/dL) – stop eplerenone immediately. (European Society of Cardiology guideline; Class I, Level A) 2
- Serum creatinine 220–310 µmol/L (≈2.5–3.5 mg/dL) – reduce the dose by 50 %. (European Society of Cardiology guideline; Class IIa, Level A) 3
Mortality and Economic Benefits
- 15 % relative risk reduction in all‑cause mortality in post‑myocardial‑infarction patients with left‑ventricular ejection fraction ≤ 40 % and heart failure (EPHESUS trial). (European Society of Cardiology guideline; Class I, Level A) 2
- High economic value derived from the mortality and morbidity reductions achieved with eplerenone therapy. (American College of Cardiology economic analysis; Class IIb, Level B) 5
- Benefits are additive to those provided by ACE inhibitors and β‑blockers in the same patient population. (European Society of Cardiology guideline; Class I, Level A) 6
Monitoring Recommendations While Continuing Eplerenone
| Parameter | Timing of Assessment after dose change |
|---|---|
| Potassium & Creatinine | 1 week, 4 weeks, then at 1, 2, 3, and 6 months |
| Frequency increase | If patient is also on ACE‑inhibitor, ARB, or NSAID (clinical judgment) |
*Serial monitoring of potassium and renal function is mandatory; serum sodium does not need routine surveillance for eplerenone safety. (European Society of Cardiology guideline; Class I, Level A) 4